Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy

In our study, we observed the long-term survival outcomes investigated for HER2-0 and HER2-low-positive breast cancer patients who received neoadjuvant chemotherapy. Between 1998 and 2020, 10,333 patients with primary breast cancer were treated, including 1373 patients with HER2-0 or HER2-low-positi...

Full description

Bibliographic Details
Main Authors: Patrik Pöschke, Peter A. Fasching, Werner Adler, Matthias Rübner, Matthias W. Beckmann, Carolin C. Hack, Felix Heindl, Arndt Hartmann, Ramona Erber, Paul Gass
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Cancers
Subjects:
breast cancer
neoadjuvant therapy
prognosis
HER2-low-positive
HER2-0
HER2
Online Access:https://www.mdpi.com/2072-6694/15/19/4678

Similar Items

Similar Items